Business Context and Reporting Period
Company: Achieve Life Sciences, Inc. (ACHV)
Filing Type: Form 8-K (Current Report)
Date of Report: November 9, 2023
Reporting Period: Second Quarter of 2023 (Q2 2023)
Context: This filing serves to announce the issuance of a press release containing financial results for Q2 2023. The detailed financial data is contained in Exhibit 99.1 and is not embedded within the text of this 8-K form.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not disclosed in the body of this filing.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in this document. The filing solely references the announcement of Q2 2023 results.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management has issued a press release regarding Q2 2023 results, but the content of that commentary is not present in this text.
Guidance and Outlook: No forward-looking guidance or outlook is provided in this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2023) for actual Q2 2023 financial figures.
- Verify the company's liquidity position and cash burn rate in the full press release, as this 8-K does not provide these numbers.
- Check for any updated operational milestones or product development status mentioned in the attached press release.
- Confirm the trading status of Common Stock (ACHV) on The Nasdaq Capital Market.